COGNITION THERAPEUTICS ANNOUNCES ALIGNMENT WITH FDA ON PIVOTAL PHASE 3 TRIAL OF ZERVIMESINE (CT1812) IN DEMENTIA WITH LEWY BODIES

Reuters · 3d ago

Please log in to view news